Regulation of α-secretase ADAM10 Expression and Activity

Overview

Journal Exp Brain Res

Specialty Neurology

Date 2011 Oct 5

PMID 21969210

Citations 31

Authors

Kristina Endres

Falk Fahrenholz

Affiliations

Soon will be listed here.

Abstract

The amyloid precursor protein (APP) has a pivotal role in pathogenesis of Alzheimer's disease (AD) via its beta- and gamma-secretase-derived cleavage products--the A-beta peptides. An alternative processing pathway provided by the alpha-secretase prevents formation of those toxic peptides and gives rise to the neurotrophic and neuroprotective cleavage product APPs-alpha. The molecular identity of the alpha-secretase has been confirmed recently, and there is consistency about ADAM10 being the most relevant and physiological enzyme of this class. It is not clear to what extent a deficiency in the catalytic activity of ADAM10 contributes to AD pathology and whether a decline occurs in aging humans. Nevertheless, ADAM10 has been suggested as a valuable target for prevention and/or for treatment of Alzheimer's disease. This review focuses on our knowledge about regulation of ADAM10 on different levels of cell physiology, such as transcription and translation, as well as protein-protein interactions and how this especially in the case of transcriptional regulation by retinoic acids might lead to the development of new therapeutic approaches.

Citing Articles

Examination of Akt and GSK3β in BDNF-mediated reductions in BACE1 activity in neuronal cells.

Baranowski B, Mohammad A, LeBlanc P, Fajardo V, MacPherson R Physiol Rep. 2024; 12(16):e70001.

PMID: 39161054 PMC: 11333542. DOI: 10.14814/phy2.70001.

Shifting the balance: soluble ADAM10 as a potential treatment for Alzheimer's disease.

Hershkovits A, Gelley S, Hanna R, Kleifeld O, Shulman A, Fishman A Front Aging Neurosci. 2023; 15:1171123.

PMID: 37266401 PMC: 10229884. DOI: 10.3389/fnagi.2023.1171123.

Pre-analytical sample handling effects on tear fluid protein levels.

Gijs M, Arumugam S, van de Sande N, Webers C, Sethu S, Ghosh A Sci Rep. 2023; 13(1):1317.

PMID: 36693949 PMC: 9873914. DOI: 10.1038/s41598-023-28363-z.

ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

Oliveira Monteiro M, Salheb Oliveira D, Manzine P, Crispim Nascimento C, Dos Santos Orlandi A, de Oliveira Gomes G Alzheimers Res Ther. 2021; 13(1):18.

PMID: 33419480 PMC: 7792035. DOI: 10.1186/s13195-020-00750-y.

Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease.

Wicinski M, Domanowska A, Wodkiewicz E, Malinowski B Int J Mol Sci. 2020; 21(8).

PMID: 32326620 PMC: 7215333. DOI: 10.3390/ijms21082749.

References

Prior R, Monning U, Weidemann A, Blennow K, Gottfries C, Masters C . Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett. 1991; 124(1):69-73. DOI: 10.1016/0304-3940(91)90824-d. View

Jarvis C, Goncalves M, Clarke E, Dogruel M, Kalindjian S, Thomas S . Retinoic acid receptor-α signalling antagonizes both intracellular and extracellular amyloid-β production and prevents neuronal cell death caused by amyloid-β. Eur J Neurosci. 2010; 32(8):1246-55. PMC: 3003897. DOI: 10.1111/j.1460-9568.2010.07426.x. View

Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L . Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006; 281(31):21745-21754. DOI: 10.1074/jbc.M602909200. View

Fahrenholz F . Alpha-secretase as a therapeutic target. Curr Alzheimer Res. 2007; 4(4):412-7. DOI: 10.2174/156720507781788837. View

Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C . Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem. 2003; 278(40):38829-39. DOI: 10.1074/jbc.M210584200. View

Yamazaki K, Mizui Y, Tanaka I . Radiation hybrid mapping of human ADAM10 gene to chromosome 15. Genomics. 1997; 45(2):457-9. DOI: 10.1006/geno.1997.4910. View

Tyler S, Dawbarn D, Wilcock G, Allen S . alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun. 2002; 299(3):373-6. DOI: 10.1016/s0006-291x(02)02635-9. View

Skovronsky D, Moore D, Milla M, Doms R, Lee V . Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J Biol Chem. 2000; 275(4):2568-75. DOI: 10.1074/jbc.275.4.2568. View

Corrigan F, Pham C, Vink R, Blumbergs P, Masters C, Van Den Heuvel C . The neuroprotective domains of the amyloid precursor protein, in traumatic brain injury, are located in the two growth factor domains. Brain Res. 2011; 1378:137-43. DOI: 10.1016/j.brainres.2010.12.077. View

10.

Reiss K, Saftig P . The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol. 2008; 20(2):126-37. DOI: 10.1016/j.semcdb.2008.11.002. View

11.

Goodger Z, Rajendran L, Trutzel A, Kohli B, Nitsch R, Konietzko U . Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway. J Cell Sci. 2009; 122(Pt 20):3703-14. DOI: 10.1242/jcs.048090. View

12.

Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K . Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry. 2007; 64(6):718-26. DOI: 10.1001/archpsyc.64.6.718. View

13.

Fellgiebel A, Kojro E, Muller M, Scheurich A, Schmidt L, Fahrenholz F . CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type. J Geriatr Psychiatry Neurol. 2008; 22(1):3-9. DOI: 10.1177/0891988708327810. View

14.

Tang K, Hynan L, Baskin F, Rosenberg R . Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci. 2005; 240(1-2):53-8. PMC: 1479090. DOI: 10.1016/j.jns.2005.09.002. View

15.

Bernstein H, Bukowska A, Krell D, Bogerts B, Ansorge S, Lendeckel U . Comparative localization of ADAMs 10 and 15 in human cerebral cortex normal aging, Alzheimer disease and Down syndrome. J Neurocytol. 2004; 32(2):153-60. DOI: 10.1023/b:neur.0000005600.61844.a6. View

16.

Cattabeni F, Colciaghi F, Di Luca M . Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28(5):763-70. DOI: 10.1016/j.pnpbp.2004.05.022. View

17.

Alfa Cisse M, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F . The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem. 2005; 280(49):40624-31. DOI: 10.1074/jbc.M506069200. View

18.

Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F . Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J. 2005; 272(22):5808-20. DOI: 10.1111/j.1742-4658.2005.04976.x. View

19.

Marcello E, Epis R, Saraceno C, Gardoni F, Borroni B, Cattabeni F . SAP97-mediated local trafficking is altered in Alzheimer disease patients' hippocampus. Neurobiol Aging. 2010; 33(2):422.e1-10. DOI: 10.1016/j.neurobiolaging.2010.09.015. View

20.

Kuhn P, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart J . ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010; 29(17):3020-32. PMC: 2944055. DOI: 10.1038/emboj.2010.167. View